Publication | Closed Access

Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers

Medicinal ChemistryMedicineSelective InhibitorPharmacotherapyAnti-cancer AgentCancer TreatmentDrug DevelopmentPharmacologyRadiation OncologyPharmaceutical ChemistryCancer ResearchDrug Discovery